AC Immune(ACIU)
1015 LAUSANNE, SwitzerlandBiotechnology
Focus: AC Immune is a Swiss-headquartered public biotech focused on neurodegenerative diseases, particularly Alzheimer's and Parkinson's, with a pipeline of tau and alpha-synuclein targeted therapies. The company is positioned as a mid-cap neurology specialist with publicly traded equity (ACIU).
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About AC Immune
AI assessmentNot HiringNo open roles listed right now. Follow AC Immune to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from AC Immune's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Optimization of Morphomer-based Alpha-synuclein PET Tracers
Parkinson DiseaseClinical Trials (1)
NCT05067192Optimization of Morphomer-based Alpha-synuclein PET Tracers
N/AHelp build intelligence for AC Immune
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.